123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic
imaging agent in evaluating patients with known or suspected neuroendocrine tumors.